Norès J M, Lignières G, Tcherdakoff P
Service de Médecine Interne, Hôpital Raymond-Poincaré, Garches.
Rev Fr Gynecol Obstet. 1988 Oct;83(10):641-5.
The authors have conducted a study of 24 women (mean age: 28 years) whose 31 pregnancies were treated with a beta-blocker (propranolol, in most cases). The overall results were compared with data from the literature. The return to normal of the blood pressure (BP) was excellent (23 cases or 74.2%). The BP was poorly controlled in 8 out of 31 cases among which were found the 4 fetal deaths of the study. There was no toxemia, no maternal complications, no theoretical neonatal effect of the beta-blockers (nor bradycardia nor hypoglycaemia). As for fetal hypotrophy, it was more frequent when the ABP did not return to normal (57% hypotrophy vs 39%) and the beta-blocker, by causing a return to normal of the BP, decreases its incidence. In addition, the mean length of treatment exceeded 2.35 weeks in normotrophic newborns in comparison with the hypotrophic newborns. Concomitantly, the return to normal of the blood pressure is improved in normotrophic newborns. The risk of fetal hypotrophy attributed to the beta-blockers is therefore confirmed and these drugs even have a favorable effect on the birth weight.
作者对24名女性（平均年龄：28岁）进行了一项研究，她们的31次妊娠使用了β受体阻滞剂（大多数情况下为普萘洛尔）进行治疗。将总体结果与文献数据进行了比较。血压（BP）恢复正常的情况非常好（23例，占74.2%）。在31例中有8例血压控制不佳，其中发现了该研究中的4例胎儿死亡。没有出现毒血症、没有母体并发症、没有β受体阻滞剂对新生儿的理论影响（既没有心动过缓也没有低血糖）。至于胎儿发育迟缓，当平均动脉压（ABP）未恢复正常时更为常见（发育迟缓率为57%，而正常恢复时为39%），并且β受体阻滞剂通过使血压恢复正常，降低了其发生率。此外，与发育迟缓的新生儿相比，营养正常的新生儿平均治疗时长超过2.35周。同时，营养正常的新生儿血压恢复正常的情况有所改善。因此，β受体阻滞剂导致胎儿发育迟缓的风险得到了证实，并且这些药物甚至对出生体重有有利影响。
